Name : Cynomolgus Her2/ErbB2 Protein
Product Source :
Recombinant Cynomolgus Her2/ErbB2 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Thr23-Thr652.[Accession | XP_005584091.2]
Molecular Weight :
The protein has a predicted MW of 70.4 kDa. Due to glycosylation, the protein migrates to 85-105 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Cynomolgus Her2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Cynomolgus Her2 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Cynomolgus Her2, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-Her2 Antibody, hFc Tag with the EC50 of 2.9ng/ml determined by ELISA.
Background :
ErbB2, also called Neu and Her2 (human epidermal growth factor receptor 2), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors.Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane.
Synonyms :
CD340; EGFR2; ErbB2; HER2; HER-2; herstatin; MLN 19; MLN19; NGL; TKR1; ERBB2; NEU; ENV; ENVW; ERVWE1; HERV7Q; HERVW
References & Citations :
(1)Tagliabue E , Balsari A , Campiglio M , et al. HER2 as a target for breast cancer therapy[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10(5):711-724.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
Lyn Protein
MIG/CXCL9 Protein
Popular categories:
AKT Serine/Threonine Kinase 2 (AKT2)
Cathepsin V/Cathepsin L2